



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 118461

TO: Devesh Khare
Location: REM-5C35&5C18
Art Unit: 1623
Thursday, April 01, 2004

Case Serial Number: 09/954953

From: Mary Jane Ruhl
Location: Biotech-Chem Library
Remsen 1-B55
Phone: 571-272-2524

maryjane.ruhl@uspto.gov

Search Notes

Examiner Khare,

Here are the results for your recent search request.

Please feel free to contact me if you have any questions about these results.

Thank you for using STIC services. We appreciate the opportunity to serve you.

Sincerely,

Mary Jane Ruhl
Technical Information Specialist
STIC
CM-1, Rm. 6-A-06
605-1155

118461

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's full Name: Devesh Khare Examiner #: 77931 Date: 04/01/2004

Art Unit: 1623 Phone Number 272-0653 Serial Number: 09/954,953

Mail Box: Remsen 5C18 and Bldg/Room Location: 5C35 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, key words, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: See Bib Data Sheet on e-dan.

Inventors (please provide full names): See Bib Data Sheet on e-dan.

Earliest priority Filing Date: See Bib Data Sheet on e-dan.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please carry out a search on the following claims:

15. (original) A chemotherapeutic combination composition comprising a chemotherapeutically effective amount of 4-desacetyl-4-methylcarbonate taxol and doxorubicin.

16. (original) The chemotherapeutic combination composition of claim 15 in a pharmaceutically acceptable carrier.

17. (original) The method for chemotherapeutic treatment of cancer in a patient in need of such treatment, comprising administering to said patient the composition of claim 16.

=> d his ful

FILE 'HCAPLUS' ENTERED AT 17:30:19 ON 01 APR 2004
 E MINOTTI GIORGIO/AU
 L1 59 SEA ABB=ON ("MINOTTI G"/AU OR "MINOTTI GIORGIO"/AU)
 E GIANNI LUCA/AU
 L2 37 SEA ABB=ON "GIANNI LUCA"/AU
 L3 5 SEA ABB=ON L1 AND L2

FILE 'REGISTRY' ENTERED AT 17:41:35 ON 01 APR 2004
 E 4-DESACETYL-4-METHYLCARBONATE, TAXOL/CN
 E DESACETYLMETHYLCARBONATE,TAXOL/CN
 L4 1 SEA ABB=ON 160084-82-2/RN
 E TAXOL/CN
 L5 1 SEA ABB=ON TAXOL/CN
 D
 L6 0 SEA ABB=ON 160084-82-2/CRN
 E DOXORUBICIN/CN
 L7 1 SEA ABB=ON DOXORUBICIN/CN
 L8 115 SEA ABB=ON 23214-92-8/CRN
 L9 0 SEA ABB=ON L8 AND L5
 L10 0 SEA ABB=ON L8 AND L4

) search for inventors

10 hits in Reg for CRN (combined
regulatory numbers)

FILE 'HCAPLUS' ENTERED AT 17:46:58 ON 01 APR 2004
 L11 2 SEA ABB=ON (L4 OR ?DESACETYLMETHYLCARBONATE,TAXOL? OR ?DESACETY
 L? (2W) ?METHYLCARBONAT? (W) ?TAXOL?)
 D AU 1-2
 L12 16453 SEA ABB=ON L7 OR ?DOXORUBICIN?
 L13 1 SEA ABB=ON L11 AND L12 *1 hit from CA Plus for the 2 complete
combined*
 L14 1 SEA ABB=ON L13 AND (?CANCER? OR ?CARCIN? OR ?NEOPLASM? OR
 ?TUMOR? OR ?TUMOUR?) *1 hit with "cancer" term, attached*

FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, JICST-EPLUS, JAPIO' ENTERED AT
 17:49:41 ON 01 APR 2004
 L15 0 SEA ABB=ON L14
 L16 0 SEA ABB=ON L13 *0 hits from other db's.*

All I can find is inventors work. If you
 would like for me to do further searching,
 please call me.

Thank you,
 Mary Jane Ruhl
 X 22524

4-desacetyl-4-methylcarboxate Taxol

Khare 09/954, 953

01/04/2004

=> d 14

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 160084-82-2 REGISTRY

CN Benzenepropanoic acid, β -(benzoylamino)- α -hydroxy-,
 (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-
 2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-6-[
 (methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-
 cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (α R, β S)- (9CI) (CA
 INDEX NAME)

OTHER CA INDEX NAMES:

CN Benzenepropanoic acid, β -(benzoylamino)- α -hydroxy-,
 12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-
 dodecahydro-4,11-dihydroxy-6-[
 (methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-
 5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester,
 [2aR-[2a α ,4 β ,4a β ,6 β ,9 α (α R*, β S*),11.a
 lpha.,12 α ,12a α ,12b α]-


FS STEREOSEARCH

MF C47 H51 N O15

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ED Entered STN: 12 Jan 1995

1 item from L14 - see "d his"

Khare 09/954, 953

01/04/2004

=> d que stat 114

L4 1 SEA FILE=REGISTRY ABB=ON 160084-82-2/RN
L7 1 SEA FILE=REGISTRY ABB=ON DOXORUBICIN/CN
L11 2 SEA FILE=HCAPLUS ABB=ON (L4 OR ?DESACETYL METHYL CARBONATE TAXOL?
OR ?DESACETYL? (2W) ?METHYL CARBONATE? (W) ?TAXOL?)
L12 16453 SEA FILE=HCAPLUS ABB=ON L7 OR ?DOXORUBICIN?
L13 1 SEA FILE=HCAPLUS ABB=ON L11 AND L12
L14 1 SEA FILE=HCAPLUS ABB=ON L13 AND (?CANCER? OR ?CARCIN? OR
?NEOPLASM? OR ?TUMOR? OR ?TUMOUR?)

L14 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:240547 HCAPLUS

DOCUMENT NUMBER: 136:257231

TITLE: Method for reducing toxicity of combined
chemotherapies

INVENTOR(S): Minotti, Giorgio; Gianni, Luca

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024179	A2	20020328	WO 2001-US27620	20010906
WO 2002024179	A3	20030313		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001088805	A5	20020402	AU 2001-88805	20010906
EP 1318794	A2	20030618	EP 2001-968565	20010906
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2002049170	A1	20020425	US 2001-954953	20010918
NO 2003001309	A	20030508	NO 2003-1309	20030321
PRIORITY APPLN. INFO.:			US 2000-234496P	P 20000922
			WO 2001-US27620	W 20010906

AB Compns. and methods are provided for use in the treatment of cancer. A method for the treatment of cancer is provided comprising administration of 4-desacetyl-4-methylcarbonate taxol and doxorubicin to a patient in need thereof. Surprisingly, it has been found that 4-desacetyl 4-Me carbonate taxol does not stimulate formation of cardiotoxic metabolic doxorubicin byproducts. Also provided with the present invention is a chemotherapeutic composition comprising a chemotherapeutically effective amount of 4-desacetyl 4-Me carbonate taxol and doxorubicin. In a further embodiment of the invention, the chemotherapeutic composition is disposed within a pharmaceutically acceptable carrier. Alternatively, each agent, 4-desacetyl 4-Me carbonate taxol and doxorubicin may be formulated sep. to facilitate sequential administration of the compns.

Applicant

Inventor Search

Khare 09/954, 953

01/04/2004

> d ibib abs ind 13 3-4

L3 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:240547 HCAPLUS
 DOCUMENT NUMBER: 136:257231
 TITLE: Method for reducing toxicity of combined chemotherapies
 INVENTOR(S): Minotti, Giorgio; Gianni, Luca
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	<i>Applicant</i>
WO 2002024179	A2	20020328	WO 2001-US27620	20010906	
WO 2002024179	A3	20030313			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2001088805	A5	20020402	AU 2001-88805	20010906	
EP 1318794	A2	20030618	EP 2001-968565	20010906	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
US 2002049170	A1	20020425	US 2001-954953	20010918	
NO 2003001309	A	20030508	NO 2003-1309	20030321	
PRIORITY APPLN. INFO.:			US 2000-234496P	P 20000922	
			WO 2001-US27620	W 20010906	

AB Compns. and methods are provided for use in the treatment of cancer. A method for the treatment of cancer is provided comprising administration of 4-desacetyl-4-methylcarbonate taxol and doxorubicin to a patient in need thereof. Surprisingly, it has been found that 4-desacetyl 4-Me carbonate taxol does not stimulate formation of cardiotoxic metabolic doxorubicin byproducts. Also provided with the present invention is a chemotherapeutic composition comprising a chemotherapeutically effective amount of 4-desacetyl 4-Me carbonate taxol and doxorubicin. In a further embodiment of the invention, the chemotherapeutic composition is disposed within a pharmaceutically acceptable carrier. Alternatively, each agent, 4-desacetyl 4-Me carbonate taxol and doxorubicin may be formulated sep. to facilitate sequential administration of the compns.

IC ICM A61K031-00

CC 1-6 (Pharmacology)

ST Section cross-reference(s): 63

ST cancer combined chemotherapy methylthiomethyltaxol doxorubicin
cardiotoxicity

IT Toxicity

(cardiotoxicity; method for reducing cardiotoxicity of combined chemotherapies using desacetyl methylcaronatetaxol in relation to formation of doxorubicin toxic metabolites)

IT Drug delivery systems

(carriers; method for reducing cardiotoxicity of combined

- chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT Lung, neoplasm
Ovary, neoplasm
(inhibitors; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT Drug delivery systems
(injections, i.m.; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT Drug delivery systems
(injections, i.p.; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT Drug delivery systems
(injections, i.v.; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT Antitumor agents
(lung; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT Antitumor agents
(mammary gland; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT Antitumor agents
Drug interactions
Human
(method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT Mammary gland
(neoplasm, inhibitors; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT Drug delivery systems
(oral; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT Antitumor agents
(ovary; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT Heart
(toxicity; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT 11062-77-4, Superoxide anion
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(doxorubicin enhancement of formation of; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT 33069-62-4, Paclitaxel 114977-28-5, Docetaxel
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(doxorubicin toxic metabolites formation stimulation by; method for reducing cardiotoxicity of combined chemotherapies using

- desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT 54193-28-1, Doxorubicinol 56149-23-6, Doxorubicinolone
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (formation; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT 24385-10-2, Doxorubicin aglycone
 RL: PKT (Pharmacokinetics); BIOL (Biological study)
 (metabolism; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT 23214-92-8, Doxorubicin
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT 160084-82-2
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)
- IT 53-57-6, NADPH
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (methylthiomethyltaxol effect on oxidation of; method for reducing cardiotoxicity of combined chemotherapies using desacetylmethylcarbonatetaxol in relation to formation of doxorubicin toxic metabolites)

L3 ANSWER 4 OF 5 HCPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:240546 HCPLUS

DOCUMENT NUMBER: 136:257230

TITLE: Method for reducing toxicity of combined chemotherapies

INVENTOR(S): Minotti, Giorgio; Gianni, Luca

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024178	A2	20020328	WO 2001-US27612	20010906
WO 2002024178	A3	20030313		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

Applicant

US 2002049169 A1 20020425 US 2001-954952 20010918
PRIOlTY APPLN. INFO.: US 2000-234708P P 20000922

AB Compns. and methods are provided for use in the treatment of cancer. A method for the treatment of cancer is provided comprising administration of 7-methylthiomethyl taxol and doxorubicin to a patient in need thereof. Surprisingly, it has been found that 7-methylthiomethyl taxol does not stimulate formation of cardiotoxic metabolic doxorubicin byproducts. Also provided with the present invention is a chemotherapeutic composition comprising a chemotherapeutically effective amount of 7-methylthiomethyl taxol and doxorubicin. In a further embodiment of the invention, the chemotherapeutic composition is disposed within a pharmaceutically acceptable carrier. Alternatively, each agent, 7-methylthiomethyl taxol and doxorubicin may be formulated sep. to facilitate sequential administration of the compns.

IC ICM A61K031-00

CC 1-6 (Pharmacology)

Section cross-reference(s): 63
ST cancer combined chemotherapy methylthiomethyItaxol doxorubicin
cardiotoxicity

IT Toxicity
(cardiotoxicity; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)

IT Drug delivery systems
(carriers; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)

IT Lung, neoplasm
Ovary, neoplasm
(inhibitors; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)

IT Drug delivery systems
(injections, i.m.; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)

IT Drug delivery systems
(injections, i.p.; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)

IT Drug delivery systems
(injections, i.v.; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)

IT Antitumor agents
(lung; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)

IT Antitumor agents
(mammary gland; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)

IT Antitumor agents
Drug interactions
Human
(method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)

IT Mammary gland
(neoplasm, inhibitors; method for reducing cardiotoxicity of combined

- cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)
- IT Drug delivery systems
(oral; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)
- IT Antitumor agents
(ovary; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)
- IT Heart
(toxicity; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)
- IT 11062-77-4, Superoxide anion
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(doxorubicin enhancement of formation of; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)
- IT 33069-62-4, Paclitaxel 114977-28-5, Docetaxel
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(doxorubicin toxic metabolites formation stimulation by; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)
- IT 54193-28-1, Doxorubicinol 56149-23-6, Doxorubicinolone
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(formation; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)
- IT 24385-10-2, Doxorubicin aglycone
RL: PKT (Pharmacokinetics); BIOL (Biological study)
(metabolism; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)
- IT 23214-92-8, Doxorubicin
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)
- IT 160237-25-2
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)
- IT 53-57-6, NADPH
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(methylthiomethyltaxol effect on oxidation of; method for reducing cardiotoxicity of combined cancer chemotherapies by using 7-methylthiomethyl taxol and doxorubicin in relation to formation of toxic doxorubicin metabolites)